EditCo Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EditCo Bio is a specialized CRISPR tools and services company spun out from the pioneering gene-editing landscape of Synthego, becoming an independent entity in early 2024. The company leverages an automated, scalable platform to deliver high-efficiency knockout and knock-in edited cells and CRISPR reagent kits to the research market, boasting >98% average editing efficiency for knockouts. Its business model is focused on providing high-value research tools and contract cell engineering services, positioning itself as a collaborative partner for academic and biopharma R&D. With access to over 1,400 cell lines and a guaranteed editing efficiency, EditCo aims to be the trusted hub for rapid, precise genome engineering.

CRISPRGene Therapy

Technology Platform

Proprietary XDel CRISPR Cell Engineering platform utilizing a multi-guide RNA strategy for high-efficiency fragment deletion knockouts and precise knock-ins. Features an automated, scalable system compatible with >1,400 immortalized, iPSC, and primary cell lines, with guaranteed editing efficiency.

Opportunities

The growing demand for complex, physiologically relevant cell models (iPSCs, primary cells) in drug discovery presents a major opportunity for EditCo's specialized engineering services.

Additionally, the company can leverage its automated platform and guaranteed efficiency to capture market share from researchers frustrated by the time and variability of in-house CRISPR editing, converting them into service clients.

Risk Factors

EditCo faces intense competition from large, established life science tools companies and other CRISPR-focused CROs.

Its technology-centric model risks obsolescence if newer gene-editing platforms surpass CRISPR-Cas9 efficiency.

Furthermore, scaling a custom service business while maintaining high margins and guaranteed outcomes is an operational challenge.

Competitive Landscape

EditCo competes in the crowded CRISPR research tools and services market against giants like Thermo Fisher Scientific and GenScript, as well as specialized players like Horizon Discovery and its former affiliate, Synthego. Its differentiation hinges on guaranteed high editing efficiency, a focus on challenging cell types (iPSCs, primary cells), and a collaborative service model, rather than competing solely on price or reagent catalog breadth.

More companies in CRISPR / Gene Editing →More companies in United States →